A study examined treatment patterns and weight outcomes for adults with overweight or obesity using glucagon-like peptide-1 (GLP-1) receptor agonists through a UK telehealth provider. The research analyzed data from 1,033,522 adults initiating either semaglutide or tirzepatide between May 1, 2024, and January 1, 2026.
Treatment Patterns and Patient Demographics
Ninety-two percent of those initiating treatment chose tirzepatide, while nine percent chose semaglutide. Provider reach was higher among women compared to men. Following a projected increase in the tirzepatide list price, there was a notable shift in treatment choices. Semaglutide initiation increased by 31.15 percentage points relative to the expected trend, while tirzepatide-to-semaglutide switching increased by 9.26 percentage points. Sensitivity analyses confirmed these changes occurred prior to the September 2025 price adjustment.
Clinical Outcomes
At twelve months, estimated weight loss was 19.93% with tirzepatide and 16.40% with semaglutide. The study involved 30,763 patients on tirzepatide and 979 patients on semaglutide. The research highlights the significant impact of treatment costs on patient selection and treatment pathways within a real-world setting. The study’s findings suggest that changes in relative pricing can substantially alter treatment patterns and, consequently, influence weight loss outcomes among individuals receiving GLP-1 receptor agonist therapy.